Lithium Hydroxide → 4-(4-(3-(1-(3-fluorobenzyl)-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl) piperazine-1-carboxamide

HRID 531687Notes

Reaction equation

HRID 531687 reaction equation
Cl.FC1C=C(C=CC=1)CN1C=C(C2C3C(=NC=C(C4C=CC(C5CCNCC5)=CC=4)C=3)N(S(C3C=CC(C)=CC=3)(=O)=O)C=2)C=N1.[F:46][C:47]1[CH:48]=[C:49]([CH:90]=[CH:91][CH:92]=1)[CH2:50][N:51]1[CH:55]=[C:54]([C:56]2[C:64]3[C:59](=[N:60][CH:61]=[C:62]([C:65]4[CH:70]=[CH:69][C:68]([N:71]5[CH2:76][CH2:75][N:74]([C:77]([NH2:79])=[O:78])[CH2:73][CH2:72]5)=[CH:67][CH:66]=4)[CH:63]=3)[N:58](S(C3C=CC(C)=CC=3)(=O)=O)[CH:57]=2)[CH:53]=[N:52]1.[OH-].[Li+]>C1COCC1.CO.O>[F:46][C:47]1[CH:48]=[C:49]([CH:90]=[CH:91][CH:92]=1)[CH2:50][N:51]1[CH:55]=[C:54]([C:56]2[C:64]3[C:59](=[N:60][CH:61]=[C:62]([C:65]4[CH:66]=[CH:67][C:68]([N:71]5[CH2:76][CH2:75][N:74]([C:77]([NH2:79])=[O:78])[CH2:73][CH2:72]5)=[CH:69][CH:70]=4)[CH:63]=3)[NH:58][CH:57]=2)[CH:53]=[N:52]1

Participants

5

Procedure

Using similar reaction conditions as described in step-iii of example-1, 4-(4-(3-(1-(3-fluorobenzyl)-1H-pyrazol-4-yl)-1-tosyl-1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl)piperazine-1-carboxamide (40 mg, 0.075 mmol) was hydrolyzed by lithium hydroxide (15 mg, 0.377 mmol) in THF/methanol/water (2/2/1 ml) to afford 10 mg (33.33% yield) of the titled compound after purification by preparative TLC(Silicagel-1000 micron) using 3% methanol in DCM as eluent. 1H NMR (DMSO-d6, 400 MHz): δ 11.7 (s, 1H), 8.46-8.41 (m, 2H), 8.27-8.26 (d, 1H), 7.99 (s, 1H), 7.72 (s, 1H), 7.63-7.61 (d, 2H), 7.42-7.35 (q, 1H), 7.15-7.05 (m, 5H), 6.04 (s, 2H), 5.39 (s, 2H), 3.45-3.43 (m, 4H), 3.13-3.11 (m, 4H). MS: m/z=496.4 (M+1), HPLC: 92.43% in method B.

Workup

  1. customreaction conditions

Sources & evidence

ORD record
ord-978035e8df6644cca7e5b9da1b5f1fc9
Source dataset
uspto-grants-2016_05
Patent number
US09353107B2

Reaction notes

Loading…